Announcements

Biomedicines (ISSN 2227-9059) is proud to present the winner of the Biomedicines Young Investigator Award—Dr. Karolina Beton-Mysur!

Dr. Karolina Beton-Mysur is an Assistant Professor of chemistry at Lodz University of Technology, Poland. Her interdisciplinary expertise spans functional nanomaterials, Raman spectroscopy, and biomedical applications, with a strong focus on developing non-invasive diagnostic tools for cancer detection using cutting-edge microspectroscopic techniques.

The following is a short interview with Dr. Karolina Beton-Mysur:

1. Could you please briefly introduce yourself to the readers?
It is a pleasure to introduce myself to the readers. My name is Karolina Beton-Mysur, and I am a chemist, nanotechnologist, and a freshly graduated PhD, currently working as an Assistant Professor at Lodz University of Technology in Poland. I specialize in functional nanomaterials, with a strong focus on non-invasive and ultrafast cancer diagnostics using cutting-edge microspectroscopic techniques.
My academic path has been a dynamic journey through the fascinating world of science—I earned my engineering degree in 2019, followed by a master’s degree with distinction in 2020, and most recently, I defended my doctoral dissertation with honors in September 2024. My research explores the frontiers of cell and tissue culture, especially in relation to the human colon, as well as the influence of various supplements such as dietary compounds, drugs, hormones, and vitamins on both micro- and macroscale systems derived from the human body. I specialize in Raman spectroscopy and imaging, as well as related spectroscopic and microscopic techniques. Although Raman spectroscopy has accompanied me from the earliest days of my scientific journey, my initial research interests were rooted in a completely different branch of chemistry. At the very beginning of my studies, I worked on a project focused on novel hybrid materials obtained via atom transfer radical polymerization (ATRP). However, everything changed when I began volunteering in a different research group—the Laboratory of Laser Molecular Spectroscopy at the Institute of Applied Radiation Chemistry at the Faculty of Chemistry at Lodz University of Technology. There, I synthesized nanoparticles for SERS measurements, and it was in that moment that my scientific path took on a new rhythm and deeper meaning.
This was followed by research on breast tissues and their differentiation with regard to cancer, with the aim of identifying specific Raman biomarkers characteristic of that disease. Around the same time, I took part in the international consortium research project VelcroMer, which I conducted at the University of Twente in the Netherlands. This project was vastly different in its scope, focusing on the surface modification of silica for use in the tire industry and exploring how polymers used in tire production change their properties after the addition of our modified silica.
As I continued, my master’s thesis work immersed me in a wide range of cell cultures and biomedical studies. The culmination of this effort was a distinction-awarded thesis in which I presented the biochemical analysis of normal and cancerous human colon cells supplemented with vitamin C, as well as the effects of oxidative stress on these cells using Raman spectroscopy and imaging. Soon after, I was accepted into a doctoral school, and from there, the scientific machine truly took off—international travels, research internships, conferences, teaching responsibilities.
During my PhD, I undertook a research stay at Ludwig-Maximilians-Universität in Munich, where I studied my beloved intestinal cells using novel techniques, including DNA Origami. I’m the kind of person who thrives on momentum and is always seeking out new challenges, collaborations, and avenues for growth. I believe deeply in movement—in the lab, in the mind, and life.
I’m an unapologetic science enthusiast—some might even say I live and breathe science. But how could I not? Everything around us is science, and so much remains to be discovered, explained, or understood on a deeper level. Life is simply too short not to ask questions and not to seek something more.
At the heart of my scientific mission lies a vision: to shape the future of medical diagnostics. My greatest dream is to see Raman spectroscopy, with all its vast potential, become part of the gold standard in preventive and diagnostic medicine, accessible to every patient. Every single day, I strive to contribute a small piece to that vision.
Throughout my career, I have led seven research projects, including international initiatives under the Polish National Agency for Academic Exchange (NAWA), and participated in five other scientific projects. I have had the privilege of being named the Best Graduate of Lodz University of Technology, and I am a recipient of several prestigious honors, including the Prof. Achmatowicz Award, the Canadian Rodkiewicz Foundation Scholarship, and most recently, the Biomedicines Young Investigator Award. I was also honored by the Committee of Analytical Chemistry of the Polish Academy of Sciences for the best PhD dissertation introducing metrological principles in chemical measurement.
I am deeply committed to fostering scientific passion in others. As a mentor in several programs for young researchers, I aim to ignite curiosity, especially in the field of chemistry, and help aspiring scientists discover their path. For my dedication to both scientific work and science communication, I was awarded the “LabO! Science Award” for lecturers who inspire beyond the classroom. I also serve as an expert at the Medical Research Agency of Poland, where I continue to contribute to advancing medical science.
Beyond the lab, I’m a world explorer at heart. I practice martial arts, find inspiration in high mountain trails, and seek freedom in the rhythm of nature. Science is my passion, but it is through balance that I find my strength and creativity.

2. Could you please share your current research direction and latest progress?
It is with sincere pleasure that I share a glimpse into my current research journey. My current research explores micro- and spectroscopic techniques as tools to better understand the biochemical signatures of cancer, especially colon cancer. I’m deeply passionate about cell and tissue cultures, particularly in the context of how external factors, such as dietary supplements, drugs, hormones, vitamins, etc., influence macro- and microscopic biological systems.
One of my most recent publications examined the effects of selective serotonin reuptake inhibitors (SSRIs)—a common class of antidepressants—as well as cytostatic drugs on human colon cells. This work reflects my broader interest in how pharmacological agents interact with normal and cancerous cells at the subcellular level.
Currently, I am managing a research project focused on the impact of addictive substances on the gut microbiota. As is well known, the use of addictive substances is steadily increasing across society. However, it is important to note that substances with high addictive potential are also commonly used in various cancer therapies as supportive agents in the treatment of persistent and long-term pain. Through advanced spectroscopic techniques and nanomechanical analysis, I am identifying metabolic biomarkers that may play a role not only in addiction mechanisms but also in how these substances affect both normal and cancerous cells. This approach allows me to investigate the complex biochemical dialogue between harmful compounds and biological systems with unprecedented sensitivity.
I am also preparing for an exciting research stay in Portugal, where I will be expanding my expertise in cutting-edge biological techniques applied to human biological material. I consider this international experience a valuable opportunity to enrich my perspective, broaden collaborations, and bring back innovative methodologies to integrate into my work in Poland.
In essence, my scientific efforts are guided by a single, persistent vision: to create tools that bring us closer to earlier, safer, and more insightful diagnoses—and, ultimately, to a deeper understanding of the human body in both health and disease. And if needed, it will become a tool that, in the future, will provide patients with rapid and unambiguous prevention, diagnosis, monitoring of disease progression, and the ability to track therapeutic outcomes.
Some may wonder why I have chosen to focus so deeply on colon cells and tissues. The answer is relatively simple. First of all, colorectal cancer is the second most commonly diagnosed type of cancer worldwide. It is, in a way, unique—it rarely gives clear warning signs, especially at an early stage, and is notoriously difficult to detect, especially since the diagnostic process remains, for many, a topic surrounded by discomfort or even shame. Despite numerous awareness campaigns, even in highly developed countries, we are still facing a major challenge in this regard.
The second reason, however, is more personal and sentimental. Before I even began my studies, my grandfather was diagnosed with colorectal cancer. I saw firsthand the struggles and obstacles that patients face, and it left a deep mark on me. In many ways, my scientific work is a tribute to someone who always believed in me, who used to tell me that no matter what life brings, I would find a way through it. And he truly believed it.
Through my research, I hope to create something meaningful—a legacy that transforms into a more accessible and compassionate reality for all. A reality in which diagnostics, not only for colorectal cancer but for various oncological diseases, becomes faster, more precise, unequivocal, and free from stigma. I want my work to raise awareness about cancer and give patients a better chance at survival and improved prognoses. And most of all, I wish for their loved ones to have the gift of time—to cherish their presence for as long as possible.

3. Could you please share with us your feelings after winning the award?
Winning this award is both an indescribable honor and a profoundly humbling experience. In the quiet moments of scientific inquiry—those long hours spent at the bench, chasing the elusive elegance of molecular transformations—recognition is rarely the end in sight. Yet to have one’s work acknowledged in this way is deeply affirming.
It feels as though the often-invisible labour of curiosity, perseverance, and at times even doubt, has been seen and celebrated. I accept this award not as a culmination, but as a spark—one that rekindles my commitment to discovery, to pushing the boundaries of what we understand, and to mentoring others on this path.
I’m especially grateful to those who came before me and opened doors I now have the privilege to walk through. This moment reminds me that science is never a solitary endeavour—it is a dialogue across generations, and I am honoured to add my voice to that conversation.
And yet, I must admit—when I first received the news, I was entirely caught off guard. The idea that a committee of such accomplished scientists, experts whom I deeply admire, had selected me as the laureate felt almost surreal. I remember that morning vividly: it was a difficult, full of variety of activities day, and at first, I barely skimmed the message. In my mind, my inner critic immediately awakened, questioning, doubting, and wondering whether it could be true. Perhaps it was a mistake? But no, it was very real.
I returned to my work, trying to stay grounded, but as I travelled between two university campuses, I reread the message. That was the moment it truly hit me. My hands trembled, and before I could even think, I let out a joyful shout, smiling so wide it felt like sunlight had broken through a storm. Of course, the very next thing I did was call my father—my parents are my most devoted supporters—to share the news.
That day will forever live in my memory. Even though the spring in Poland was still rather chilly, around me the world felt like a warm, blazing summer.
Moments like this remind me not only of how far we can come with resilience and passion, but also of the quiet strength it takes to believe, truly believe, that we are worthy of such moments.

4. Could you please share the most impressive breakthrough in your research career, either in terms of ideas or research results?
One of the most defining moments in my scientific career—and the achievement I consider the most impactful—was the development of four independent, fully original protocols for the deparaffinization of biological samples, specifically intraoperative tissue sections. These protocols were designed with precision and innovation, and what made them particularly groundbreaking was their role in proving that only fresh, unfixed tissues can serve as a reliable foundation for accurate and unambiguous results obtained through Raman spectroscopy and imaging techniques.
In this research, I addressed a critical but often overlooked aspect of biomedical analysis: sample preparation. While frequently treated as a mere technicality, it has profound implications for the accuracy and reproducibility of diagnostic outcomes. I demonstrated that the type and quality of biological material used, especially the distinction between fresh and paraffin-embedded tissues, significantly affect the ability to detect cancer markers and extract meaningful biochemical information from spectroscopic data. My work showed that fresh tissues preserve the biochemical integrity necessary for precise, label-free diagnostics at the molecular level.
What makes this breakthrough particularly meaningful to me is not only its scientific and clinical relevance, but also the context in which it emerged. This idea began to take shape during my undergraduate engineering studies, at a time when I was still learning to navigate the world of scientific inquiry. It evolved through years of questioning, refining, and believing that even as a young researcher, I could challenge well-established routines and offer something valuable to both the scientific community and medical practice.
One of the challenges I encountered was the absence of standardized, widely accepted deparaffinization protocols, even among experienced clinical researchers and pathologists. This lack of consistency often leads to discrepancies in data interpretation, undermining the potential of techniques like Raman spectroscopy in a clinical setting. The introduction of well-structured, technologically sound deparaffinization procedures could significantly streamline spectroscopic diagnostics, benefiting not only patient outcomes but also the efficiency of healthcare systems.
Ultimately, this work reaffirmed my belief that the smallest experimental details can lead to the greatest scientific insights, and that innovation often begins with the courage to question what is routinely accepted. It also reflects the very essence of what continues to drive me as a scientist: the desire to bridge disciplines, rethink conventions, and bring chemistry closer to the people it ultimately serves—the patients.
I am also immensely proud of my most recent results, currently under review, which were achieved in collaboration with esteemed researchers from the Institute of Applied Radiation Chemistry at the Faculty of Chemistry of my Alma Mater, Lodz University of Technology. In this research, we investigated the spectroscopic properties of a promising photosensitizer for photodynamic therapy (PDT). Using a combination of Raman imaging, electronic absorption spectroscopy, fluorescence spectroscopy, and transient absorption spectroscopy, we aimed to determine both the distribution of the photosensitizer within human colorectal tissue and its dynamic behavior in aqueous media, including environments enriched with living cells.
Our findings revealed that, following supplementation of human colorectal cancer cells with the photosensitizer, the compound preferentially accumulates in structures that are metabolically significant—a discovery that opens new avenues for targeted therapeutic strategies. While I hope to share more details soon, what I can already underscore is that the results strongly suggest the potential for efficient singlet oxygen generation upon stimulus activation by the photosensitizer during photodynamic anti-cancer treatment. This work represents not only a meaningful scientific collaboration but also a step closer to more selective and effective oncological therapies, and it exemplifies my ongoing commitment to translating chemical insight into tangible clinical impact.

5. Do you have any other suggestions for how journals and publishers can further support young researchers and the academic community?
Indeed, I believe journals and publishers hold immense, often underutilized potential to shape the landscape for young researchers in profoundly meaningful ways. Beyond the traditional roles of gatekeeping and dissemination, they can become true partners in fostering a more inclusive, transparent, and vibrant scientific community. Journals and publishers are uniquely positioned to not only disseminate scientific knowledge but also to actively shape the culture in which that knowledge is created. For young researchers—especially those at the intersection of early career and underrepresented identity—this support can be transformative.

First and foremost, I would advocate for greater openness—not only in terms of access to published work, but also in the review process itself. Transparent peer review, mentorship-style feedback for early-career authors (maybe in a separate issue), and the recognition of reviewers’ contributions can transform publishing into a more constructive, dialogic experience rather than a distant judgment. Beyond ensuring access and visibility, I would encourage journals to adopt a more holistic view of their mission. Science is not produced in a vacuum—it is born of mentorship, equity, and opportunity. Initiatives such as mentoring schemes linked to the publication process, constructive and developmental peer review, and dedicated sections for early-career voices can offer not only validation but growth.
Secondly, I envision journals as platforms not only for results, but for the process of science. Allowing space for negative results, methodological insights, and interdisciplinary experiments—especially those that don’t neatly “fit”—could encourage creativity and reduce the pressure to only present polished, publishable stories. After all, science often advances not in leaps, but in well-documented stumbles.
Moreover, I feel strongly that journals can become more intentional in amplifying diverse perspectives, particularly those of women and other historically marginalized groups. Spotlighting female-led research, offering editorial board positions to emerging women scholars—these steps signal that excellence comes in many forms, and that inclusion is not ornamental, but essential.
I also believe in the quiet power of representation. When a young scientist sees a name like hers in the byline, in the reviewer list, in the editor’s note, she understands—perhaps for the first time—that she too belongs in the architecture of science. Journals can help build that architecture thoughtfully.
In the end, to support young researchers is not only to offer them a platform, but to invite them into the ongoing authorship of the scientific enterprise itself—one that is rigorous, yes, but also humane, collaborative, and richly diverse. In essence, I believe journals could evolve from being static repositories into dynamic ecosystems—ones that nurture not just knowledge, but also the people who pursue it.

In my field—spectroscopy and chemometrics—we are already witnessing this transformation. Interestingly, several methods traditionally used in chemometrics, such as Principal Component Analysis (PCA), Partial Least Squares Discriminant Analysis (PLS-DA), Support Vector Machines (SVM), and Cluster Analysis (like k-means), are now recognized as foundational forms of artificial intelligence and machine learning. So in a way, we’ve been walking hand in hand with AI for some time now—perhaps even before we fully realized it.
Looking ahead, I believe the most exciting developments will emerge in areas such as deep learning, time-series analysis, and transfer learning. These tools will allow us to not only better interpret complex spectral data but also monitor chemical and metabolic reactions in real time, recognize intricate hidden patterns, and adapt models across different datasets or instruments. The potential of recurrent neural networks (RNNs) and LSTM architectures to interpret evolving spectral profiles, such as those in real-time Raman monitoring, is particularly fascinating.
Of course, while I welcome these innovations with open arms, I also feel a gentle responsibility to remind fellow researchers, especially the younger generation, to remain grounded in their scientific judgment. AI is a remarkable tool, not a substitute for understanding. Let us use it to deepen, not replace, our thinking. Let us remain unique in our scientific voice, never losing the joy of questioning just because the machine has answered.
So yes, while AI-enhanced chemistry is undeniably a rising star, I remain equally enchanted by all the “quieter” topics—those that lie patiently on the periphery, waiting for someone curious enough to ask the right question.

7. Do you have anything to say to your fellow scholars?
It is with genuine joy that I answer this question. What I would like to say to my fellow scholars comes straight from the heart and is deeply rooted in personal experience: don’t be afraid to aim high. The world of science is vast, unpredictable, and at times demanding—but it has never been reserved for a chosen few. I’ve been told many times that, as a woman in chemistry, my path would be limited. That coming from a small town meant my future was already defined and constrained. And you know what? None of that turned out to be true.
So please, never let anyone else define what you are capable of. Stay true to your work—with tenderness toward science, humility in the face of knowledge, and the unwavering belief that your voice matters. The most important thing is that what you do brings you joy and a sense of meaning.
It’s not worth working solely to achieve some pre-defined notion of success, because success can be elusive, unpredictable, and its definition tends to evolve over time. What is worth pursuing is the discipline of taking consistent, even the smallest, steps every single day. These modest efforts, though often overlooked, are what eventually pave the way to extraordinary things.
As an old Chinese proverb beautifully says: "Do not fear going slowly; fear only standing still”.
And in that spirit, I try to see science not just as a destination, but as a journey. Because it is the journey that shapes us, teaches us, and surprises us. It is along the way that we meet the people who inspire us, challenge us, and remind us why we started. It is the journey that makes even failure taste like growth, rather than defeat.
Value your failures—they are what make us strong. Without them, we would be like delicate glass—beautiful in theory, but brittle at the first touch of hardship. And science is not about fragility; it’s about resilience, curiosity, and learning to harness the wind rather than hide from it. Because adversity, when embraced with courage, can lift us higher than we ever thought possible.
And when it feels like everything is working against you, remember, an airplane takes off against the wind, not with it.
From the bottom of my heart, I wish each of you courage, tenderness for your craft, and belief in the value of your work. Even—and perhaps especially—when the road ahead looks nothing like a straight path.

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue	quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article
	Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue	green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article
	Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue	ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article
	Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue	computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article
	Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue	sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article
	Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue	bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article

The “Cell Biology and Pathology” Section covers all aspects of this general field, from molecular machines that enable or adversely modify cell function to the pathology of complete organisms. Both review articles and original research contributions are welcome, as long as they conform to the highest scientific standards. Contributions that explore the origin of diseases at the molecular level, such as structural, biochemical, and genetic studies of receptors, oncogenes, tumor suppressors and regulatory proteins, signal pathways, and RNA/DNA, as well as articles that propose new routes for the cure and prevention of diseases, are of particular interest. Cutting-edge diagnostic tools ranging from PCR to magnetic resonance, as applied to the detection of cellular or organismic pathological dysfunctions on all levels, will be accepted. In this context, we are pleased to feature some recently published papers from the “Cell Biology and Pathology” Section in Biomedicines (ISSN: 2227-9059), which provide valuable insights into this exciting field.

1. “Aldose Reductase as a Key Target in the Prevention and Treatment of Diabetic Retinopathy: A Comprehensive Review”
by Alexandra-Ioana Dănilă, Laura Andreea Ghenciu, Emil Robert Stoicescu, Sorin Lucian Bolintineanu, Roxana Iacob, Mihai-Alexandru Săndesc and Alexandra Corina Faur
Biomedicines 2024, 12(4), 747; https://doi.org/10.3390/biomedicines12040747
Available online: https://www.mdpi.com/2227-9059/12/4/747

2. “The Role of Fibroblasts in Skin Homeostasis and Repair”
by Federica Boraldi, Francesco Demetrio Lofaro, Susanna Bonacorsi, Alessia Mazzilli, Maria Garcia-Fernandez and Daniela Quaglino
Biomedicines 2024, 12(7), 1586; https://doi.org/10.3390/biomedicines12071586
Available online: https://www.mdpi.com/2227-9059/12/7/1586

3. “Zebrafish as a Model for Cardiovascular and Metabolic Disease: The Future of Precision Medicine”
by Ramcharan Singh Angom and Naga Malleswara Rao Nakka
Biomedicines 2024, 12(3), 693; https://doi.org/10.3390/biomedicines12030693
Available online: https://www.mdpi.com/2227-9059/12/3/693

4. “Is Chronic Kidney Disease Due to Cadmium Exposure Inevitable and Can It Be Reversed?”
by Soisungwan Satarug
Biomedicines 2024, 12(4), 718; https://doi.org/10.3390/biomedicines12040718
Available online: https://www.mdpi.com/2227-9059/12/4/718

5. “Roles of Macrophages and Endothelial Cells and Their Crosstalk in Acute Lung Injury”
by Sara Osorio-Valencia and Bisheng Zhou
Biomedicines 2024, 12(3), 632; https://doi.org/10.3390/biomedicines12030632
Available online: https://www.mdpi.com/2227-9059/12/3/632

6. “UCP2, a Member of the Mitochondrial Uncoupling Proteins: An Overview from Physiological to Pathological Roles”
by Salvatore Nesci and Speranza Rubattu
Biomedicines 2024, 12(6), 1307; https://doi.org/10.3390/biomedicines12061307
Available online: https://www.mdpi.com/2227-9059/12/6/1307

7. “Latest Advances in Chondrocyte-Based Cartilage Repair”
by Li Yue, Ryan Lim and Brett D. Owens
Biomedicines 2024, 12(6), 1367; https://doi.org/10.3390/biomedicines12061367
Available online: https://www.mdpi.com/2227-9059/12/6/1367

8. “Understanding Tendon Fibroblast Biology and Heterogeneity”
by Sarah E. DiIorio, Bill Young, Jennifer B. Parker, Michelle F. Griffin and Michael T. Longaker
Biomedicines 2024, 12(4), 859; https://doi.org/10.3390/biomedicines12040859
Available online: https://www.mdpi.com/2227-9059/12/4/859

9. “Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting”
by Dario Troise, Barbara Infante, Silvia Mercuri, Valeria Catalano, Elena Ranieri and Giovanni Stallone
Biomedicines 2024, 12(6), 1240; https://doi.org/10.3390/biomedicines12061240
Available online: https://www.mdpi.com/2227-9059/12/6/1240

10. “Senescent Macrophages Release Inflammatory Cytokines and RNA-Loaded Extracellular Vesicles to Circumvent Fibroblast Senescence”
by Camille Laliberté, Bianca Bossé, Véronique Bourdeau, Luis I. Prieto, Genève Perron-Deshaies, Nhung Vuong-Robillard, Sebastian Igelmann, Lisbeth Carolina Aguilar, Marlene Oeffinger, Darren J. Baker et al.
Biomedicines 2024, 12(5), 1089; https://doi.org/10.3390/biomedicines12051089
Available online: https://www.mdpi.com/2227-9059/12/5/1089

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link:
https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The “Immunology and Immunotherapy” Section publishes reviews and original peer-reviewed papers of a high scientific level covering all aspects of immunology and oncoimmunology. Papers aim to uncover modulations in the immune system, active and passive immunotherapies, diagnostic tests based on specific markers, and new technologies to identify novel predictive factors to respond to immunotherapy. Topics include but are not limited to in vivo/in vitro immune response research; targeted therapies (including antibody research and vaccine research); virotherapy and oncolytic vaccines; use of nanoparticles and microvesicles for developing immunotherapeutics; etc.

1. “Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator”
by Mostafa Hamada, Kyle Steven Varkoly, Omer Riyadh, Roxana Beladi, Ganesh Munuswamy-Ramanujam, Alan Rawls, Jeanne Wilson-Rawls, Hao Chen, Grant McFadden and Alexandra R. Lucas
Biomedicines 2024, 12(6), 1167; https://doi.org/10.3390/biomedicines12061167
Available online: https://www.mdpi.com/2227-9059/12/6/1167

2. “Pathogenesis, Prophylaxis, and Treatment of Candida auris”
by Madalina Preda, Razvan Daniel Chivu, Lia Mara Ditu, Oana Popescu and Loredana Sabina Cornelia Manolescu
Biomedicines 2024, 12(3), 561; https://doi.org/10.3390/biomedicines12030561
Available online: https://www.mdpi.com/2227-9059/12/3/561

3. “Anti-Inflammatory Therapeutic Mechanisms of Isothiocyanates: Insights from Sulforaphane”
by Solomon Habtemariam
Biomedicines 2024, 12(6), 1169; https://doi.org/10.3390/biomedicines12061169
Available online: https://www.mdpi.com/2227-9059/12/6/1169

4. “Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation”
by Mary Garvey
Biomedicines 2024, 12(4), 740; https://doi.org/10.3390/biomedicines12040740
Available online: https://www.mdpi.com/2227-9059/12/4/740

5. “The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases”
by Carmela Coccia, Francesco Bonomi, Anna Lo Cricchio, Edda Russo, Silvia Peretti, Giulia Bandini, Gemma Lepri, Francesca Bartoli, Alberto Moggi-Pignone, Serena Guiducci et al.
Biomedicines 2024, 12(8), 1760; https://doi.org/10.3390/biomedicines12081760
Available online: https://www.mdpi.com/2227-9059/12/8/1760

6. “The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury”
by Gillene Santos Ferreira, Melissa Lopes Frota, Maria José Dias Gonzaga, Maria de Fátima Fernandes Vattimo and Camila Lima
Biomedicines 2024, 12(5), 931; https://doi.org/10.3390/biomedicines12050931
Available online: https://www.mdpi.com/2227-9059/12/5/931

7. “Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and Immune-Related Diseases”
by Chieh-Yu Shen, Cheng-Hsun Lu, Chiao-Feng Cheng, Ko-Jen Li, Yu-Min Kuo, Cheng-Han Wu, Chin-Hsiu Liu, Song-Chou Hsieh, Chang-Youh Tsai and Chia-Li Yu
Biomedicines 2024, 12(8), 1699; https://doi.org/10.3390/biomedicines12081699
Available online: https://www.mdpi.com/2227-9059/12/8/1699

8. “Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective”
by Marco Caminati, Matteo Maule, Roberto Benoni, Diego Bagnasco, Bianca Beghè, Fulvio Braido, Luisa Brussino, Paolo Cameli, Maria Giulia Candeliere, Giovanna Elisiana Carpagnano et al.
Biomedicines 2024, 12(2), 390; https://doi.org/10.3390/biomedicines12020390
Available online: https://www.mdpi.com/2227-9059/12/2/390

9. “Unraveling the Link between Insulin Resistance and Bronchial Asthma”
by Konstantinos Bartziokas, Andriana I. Papaioannou, Fotios Drakopanagiotakis, Evanthia Gouveri, Nikolaos Papanas and Paschalis Steiropoulos
Biomedicines 2024, 12(2), 437; https://doi.org/10.3390/biomedicines12020437
Available online: https://www.mdpi.com/2227-9059/12/2/437

10. “Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases”
by Katarzyna Antosz, Joanna Batko, Marta Błażejewska, Antoni Gawor, Jakub Sleziak and Krzysztof Gomułka
Biomedicines 2024, 12(7), 1531; https://doi.org/10.3390/biomedicines12071531
Available online: https://www.mdpi.com/2227-9059/12/7/1531

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link:
https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The “Molecular and Translational Medicine” Section publishes reviews and original peer-reviewed papers which aim to cover studies concerning disease pathogenesis at the molecular or physiological level, as well as basic preclinical, clinical, and translational aspects. We encourage scientists to submit their results that have the potential for application in human disease, as well as research obtained from clinical trials or animal models of human diseases that has the potential to shed light on the underlying causes of various human diseases and cancer, allowing for the development of future human medicines, medical devices, and diagnostics. In this context, we are pleased to feature some recently published papers on molecular and translational medicine in Biomedicines (ISSN: 2227-9059), which will provide valuable insights into this exciting field.

1. “Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare”
by Alex E. Mohr, Carmen P. Ortega-Santos, Corrie M. Whisner, Judith Klein-Seetharaman and Paniz Jasbi
Biomedicines 2024, 12(7), 1496; https://doi.org/10.3390/biomedicines12071496
Available online: https://www.mdpi.com/2227-9059/12/7/1496

2. “Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers”
by Giancarlo Trimarchi, Lucio Teresi, Roberto Licordari, Alessandro Pingitore, Fausto Pizzino, Patrizia Grimaldi, Danila Calabrò, Paolo Liotta, Antonio Micari, Cesare de Gregorio et al
Biomedicine. 2024, 12(5), 1051; https://doi.org/10.3390/biomedicines12051051
Available online: https://www.mdpi.com/2227-9059/12/5/1051

3. “Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies”
by Lina Noelia Jurado-Priego, Cristina Cueto-Ureña, María Jesús Ramírez-Expósito and José Manuel Martínez-Martos
Biomedicines 2024, 12(7), 1543; https://doi.org/10.3390/biomedicines12071543
Available online: https://www.mdpi.com/2227-9059/12/7/1543

4. “Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions”
by Rajesh Jha, Sara Lopez-Trevino, Haritha R. Kankanamalage and Jay C. Jha
Biomedicines 2024, 12(5), 1098. https://doi.org/10.3390/biomedicines12051098
Available online: https://www.mdpi.com/2227-9059/12/5/1098

5. “Immunosuppression in Sepsis: Biomarkers and Specialized Pro-Resolving Mediators”
by Cristina M. Padovani and Kingsley Yin
Biomedicines 2024, 12(1), 175. https://doi.org/10.3390/biomedicines12010175
Available online: https://www.mdpi.com/2227-9059/12/1/175

6. “Osteoporosis, Osteoarthritis, and Subchondral Insufficiency Fracture: Recent Insights”
by Shunichi Yokota, Hotaka Ishizu, Takuji Miyazaki, Daisuke Takahashi, Norimasa Iwasaki and Tomohiro Shimizu
Biomedicines 2024, 12(4), 843; https://doi.org/10.3390/biomedicines12040843
Available online: https://www.mdpi.com/2227-9059/12/4/843

7. “Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline”
by Antonio Lardaro, Ludovica Quarta, Stefania Pagnotta, Giorgio Sodero, Sandro Mariani, Maria Del Ben, Giovambattista Desideri, Evaristo Ettorre and Francesco Baratta
Biomedicines 2024, 12(8),1750; https://doi.org/10.3390/biomedicines12081750
Available online: https://www.mdpi.com/2227-9059/12/8/1750

8. “Current Knowledge on the Use of Neuromonitoring in Thyroid Surgery”
by Beata Wojtczak, Karolina Sutkowska-Stępień, Mateusz Głód, Krzysztof Kaliszewski, Krzysztof Sutkowski and Marcin Barczyński
Biomedicines 2024, 12(3), 675; https://doi.org/10.3390/biomedicines12030675
Available online: https://www.mdpi.com/2227-9059/12/3/675

9. “Carriers of Heterozygous Loss-of-Function ACE Mutations Are at Risk for Alzheimer’s Disease”
by Sergei M. Danilov, Ivan A. Adzhubei, Alexander J. Kozuch, Pavel A. Petukhov, Isolda A. Popova, Ananyo Choudhury, Dhriti Sengupta and Steven M. Dudek
Biomedicines 2024, 12(1), 162; https://doi.org/10.3390/biomedicines12010162
Available online: https://www.mdpi.com/2227-9059/12/1/162

10. “Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?”
by Mohammad Jad Moussa, Matthew T. Campbell and Omar Alhalabi
Biomedicines 2024, 12(3), 519; https://doi.org/10.3390/biomedicines12030519
Available online: https://www.mdpi.com/2227-9059/12/3/519

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines. 

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit. 

Biomedicines Editorial Office

The “Gene and Cell Therapy” Section publishes reviews and original peer-reviewed papers. This section of Biomedicines aims to rapidly publish contributions on all aspects of the latest research results concerning gene and cell therapy. We encourage submissions of manuscripts that provide novel and mechanistic insights, including but not limited to gene transfer; vector development and design; autologous and allogeneic cell therapies (hematopoietic and mesenchymal stem cell therapies); the development of genes, peptides, proteins, oligonucleotides, and cell therapies to correct genetic and acquired diseases; vaccine development; preclinical target validation; and other research aspects. In this context, we are pleased to feature some recently published papers from the “Gene and Cell Therapy” Section in Biomedicines (ISSN: 2227-9059), which will provide valuable insights into this exciting field.

1. “Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma”
by Alessandro Allegra, Giuseppe Murdaca, Giuseppe Mirabile and Sebastiano Gangemi
Biomedicines 2024, 12(3), 514; https://doi.org/10.3390/biomedicines12030514
Available online: https://www.mdpi.com/2227-9059/12/3/514

2. “MicroRNA Monitoring in Human Alveolar Macrophages from Patients with Smoking-Related Lung Diseases: A Preliminary Study”
by Davida Mirra, Renata Esposito, Giuseppe Spaziano, Liberata Sportiello, Francesca Panico, Antonio Squillante, Maddalena Falciani, Ida Cerqua , Luca Gallelli, Erika Cione and Bruno D’Agostino
Biomedicines 2024, 12(5), 1050; https://doi.org/10.3390/biomedicines12051050
Available online: https://www.mdpi.com/2227-9059/12/5/1050

3. “Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome”
by Remi Sumiyoshi, Tomohiro Koga and Atsushi Kawakami
Biomedicines 2024, 12(6), 1141; https://doi.org/10.3390/biomedicines12061141
Available online: https://www.mdpi.com/2227-9059/12/6/1141

4. “Structural Changes Likely Cause Chemical Differences between Empty and Full AAV Capsids”
by Caryn L. Heldt, Molly A. Skinner and Ganesh S. Anand
Biomedicines 2024, 12(9), 2128; https://doi.org/10.3390/biomedicines12092128
Available online: https://www.mdpi.com/2227-9059/12/9/2128

5. “Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer”
by Aseem Rai Bhatnagar, Farzan Siddiqui, Gazala Khan, Robert Pompa, David Kwon and Shyam Nyati
Biomedicines 2024, 12(5), 1065; https://doi.org/10.3390/biomedicines12051065
Available online: https://www.mdpi.com/2227-9059/12/5/1065

6. “Potential Causal Association between C-Reactive Protein Levels in Age-Related Macular Degeneration: A Two-Sample Mendelian Randomization Study”
by Byung Woo Yoon, Young Lee and Je Hyun Seo
Biomedicines 2024, 12(4), 807; https://doi.org/10.3390/biomedicines12040807
Available online: https://www.mdpi.com/2227-9059/12/4/807

7. “A Comprehensive Exploration of Therapeutic Strategies in Inflammatory Bowel Diseases: Insights from Human and Animal Studies”
by Inês Esteves Dias, Isabel Ribeiro Dias, Teresa Franchi-Mendes, Carlos Antunes Viegas and Pedro Pires Carvalho
Biomedicines 2024, 12(4), 735; https://doi.org/10.3390/biomedicines12040735
Available online: https://www.mdpi.com/2227-9059/12/4/735

8. “Regenerative Therapy for Corneal Scarring Disorders”
by Christine Chandran, Mithun Santra, Elizabeth Rubin, Moira L. Geary and Gary Hin-Fai Yam
Biomedicines 2024, 12(3), 649; https://doi.org/10.3390/biomedicines12030649
Available online: https://www.mdpi.com/2227-9059/12/3/649

9. “Application of SWATH Mass Spectrometry and Machine Learning in the Diagnosis of Inflammatory Bowel Disease Based on the Stool Proteome”
by Elmira Shajari, David Gagné, Mandy Malick, Patricia Roy, Jean-François Noël, Hugo Gagnon, Marie A. Brunet, Maxime Delisle, François-Michel Boisvert and Jean-François Beaulieu
Biomedicines 2024, 12(2), 333; https://doi.org/10.3390/biomedicines12020333
Available online: https://www.mdpi.com/2227-9059/12/2/333

10. “CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo”
by Eunhee Park, Hui-jin Mun, Eunju Seo, Seojin Hwang, Jae Hee Lee, Sukgil Song, Hyeran Sung, Hoi-Yul Kim and Mi-Jin Kwon
Biomedicines 2024, 12(1), 248; https://doi.org/10.3390/biomedicines12010248
Available online: https://www.mdpi.com/2227-9059/12/1/248

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:

This Section is currently open for submissions. Papers may be submitted via the following link:

https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:

If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The Section “Molecular Genetics and Genetic Diseases” covers the basic and translational aspects of human genetic diseases and genomics research, from fundamental molecular investigation to preclinical animal models. In particular, this Section aims to facilitate the rapid publication of innovative research encompassing the genetic basis of human health and disease, as well as the treatment of genetic disorders and heritable or acquired cancers. We welcome submissions that apply new and emerging technologies in the fields of genomics, transcriptomics and bioinformatic tools to advance knowledge in human genetic diseases.

1. “Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future”
by Mohammed Tiseer Abbas, Nima Baba Ali, Juan M. Farina, Ahmed K. Mahmoud, Milagros Pereyra, Isabel G. Scalia, Moaz A. Kamel, Timothy Barry, Steven J. Lester, Charles R. Cannan et al.
Biomedicines 2024, 12(3), 682; https://doi.org/10.3390/biomedicines12030682
Available online: https://www.mdpi.com/2227-9059/12/3/682#

2. “Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS)”
by John A. D’Elia and Larry A. Weinrauch
Biomedicines 2024, 12(5), 978; https://doi.org/10.3390/biomedicines12050978
Available online: https://www.mdpi.com/2227-9059/12/5/978

3. “Predictors of Successful Testicular Sperm Extraction: A New Era for Men with Non-Obstructive Azoospermia”
by Aris Kaltsas, Sofoklis Stavros, Zisis Kratiras, Athanasios Zikopoulos, Nikolaos Machairiotis, Anastasios Potiris, Fotios Dimitriadis, Nikolaos Sofikitis, Michael Chrisofos and Athanasios Zachariou
Biomedicines 2024, 12(12), 2679; https://doi.org/10.3390/biomedicines12122679
Available online: https://www.mdpi.com/2227-9059/12/12/2679

4. “Burning Mouth Syndrome Treated with Low-Level Laser and Clonazepam: A Randomized, Single-Blind Clinical Trial”
by Ana Garcia Martinez, Pia Lopez-Jornet, Luis Pardo Marin, Eduardo Pons-Fuster and Asta Tvarijonaviciute
Biomedicines 2024, 12(5), 1048; https://doi.org/10.3390/biomedicines12051048
Available online: https://www.mdpi.com/2227-9059/12/5/1048

5. “Physiological Consequences of Nonsense-Mediated Decay and Its Role in Adaptive Responses”
by Zhengxin Ma, Ratna Sharma and Aric N. Rogers
Biomedicines 2024, 12(5), 1110; https://doi.org/10.3390/biomedicines12051110
Available online: https://www.mdpi.com/2227-9059/12/5/1110

6. “Sarcoidosis Associated Pulmonary Hypertension”
by Alexander Liu, Laura C. Price, Rakesh Sharma, Athol U. Wells and Vasileios Kouranos
Biomedicines 2024, 12(1), 177; https://doi.org/10.3390/biomedicines12010177
Available online: https://www.mdpi.com/2227-9059/12/1/177

7. “Overexpression of SMYD3 Promotes Autosomal Dominant Polycystic Kidney Disease by Mediating Cell Proliferation and Genome Instability”
by Ewud Agborbesong, Julie Xia Zhou, Hongbing Zhang, Linda Xiaoyan Li, Peter C. Harris, James P. Calvet and Xiaogang Li
Biomedicines 2024, 12(3), 603; https://doi.org/10.3390/biomedicines12030603
Available online: https://www.mdpi.com/2227-9059/12/3/603

8. “Epigenetic Regulation of DNA Methylation and RNA Interference in Gastric Cancer: A 2024 Update”
by Iulia Lupan, Vasile Bintintan, Diana Deleanu and Gabriel Samasca
Biomedicines 2024, 12(9), 2001; https://doi.org/10.3390/biomedicines12092001
Available online: https://www.mdpi.com/2227-9059/12/9/2001

9. “The Influence of Tacrolimus Exposure and Metabolism on the Outcomes of Kidney Transplants”
by Rima Maslauskiene, Ruta Vaiciuniene, Aurelija Radzeviciene, Peteris Tretjakovs, Gita Gersone, Edgaras Stankevicius and Inga Arune Bumblyte
Biomedicines 2024, 12(5), 1125; https://doi.org/10.3390/biomedicines12051125
Available online: https://www.mdpi.com/2227-9059/12/5/1125

10. “Current Immunotherapy Treatments of Primary Breast Cancer Subtypes”
by Savannah R. Brown and Emilie E. Vomhof-DeKrey
Biomedicines 2024, 12(4), 895; https://doi.org/10.3390/biomedicines12040895
Available online: https://www.mdpi.com/2227-9059/12/4/895

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link:
https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The “Nanomedicine and Nanobiology” Section publishes reviews and original peer-reviewed papers of a high scientific level covering all aspects of nanomedicine. Papers aim to uncover the synthesis, bioavailability, and biodistribution of nanomedicines; the delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; and interactions of nanomaterials with cells, tissues, and living organisms. In this context, we are pleased to feature some recently published papers from the “Nanomedicine and Nanobiology” Section in Biomedicines (ISSN: 2227-9059), which provide valuable insights into this exciting field.

1. “An In Vitro Model to Assess Early Immune Markers Following Co-Exposure of Epithelial Cells to Carbon Black (Nano)Particles in the Presence of S. aureus: A Role for Stressed Cells in Toxicological Testing”
by Scott Brown, Stephen J. Evans, Michael J. Burgum, Kirsty Meldrum, Jack Herridge, Blessing Akinbola, Llinos G. Harris, Rowena Jenkins, Shareen H. Doak, Martin J. D. Clift et al.
Biomedicines 2024, 12(1), 128; https://doi.org/10.3390/biomedicines12010128
Available online: https://www.mdpi.com/2227-9059/12/1/128

2. “Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections”
by Lídia Leonize Rodrigues Matias, Karla Suzanne Florentino da Silva Chaves Damasceno, Annemberg Salvino Pereira, Thaís Souza Passos and Ana Heloneida de Araujo Morais
Biomedicines 2024, 12(1), 176; https://doi.org/10.3390/biomedicines12010176
Available online: https://www.mdpi.com/2227-9059/12/1/176

3. “Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review”
by Stefana Maria Moisa, Alexandru Burlacu, Lacramioara Ionela Butnariu, Corina Maria Vasile, Crischentian Brinza, Elena Lia Spoiala, Alexandra Maștaleru, Maria Magdalena Leon, Solange Tamara Rosu, Radu Vatasescu et al.
Biomedicines 2024, 12(1), 185; https://doi.org/10.3390/biomedicines12010185
Available online: https://www.mdpi.com/2227-9059/12/1/185

4. “Biological Effects of Small Sized Graphene Oxide Nanosheets on Human Leukocytes”
by Michele Aventaggiato, Federica Valentini, Daniela Caissutti, Michela Relucenti, Marco Tafani, Roberta Misasi, Alessandra Zicari, Sara Di Martino, Sara Virtuoso, Anna Neri et al.
Biomedicines 2024, 12(2), 256; https://doi.org/10.3390/biomedicines12020256
Available online: https://www.mdpi.com/2227-9059/12/2/256

5. “Advancing Cancer Treatment: Enhanced Combination Therapy through Functionalized Porous Nanoparticles”
by Kibeom Kim and Myoung-Hwan Park
Biomedicines 2024, 12(2), 326; https://doi.org/10.3390/biomedicines12020326
Available online: https://www.mdpi.com/2227-9059/12/2/326

6. “Nanomaterials Based on 2,7,12,17-Tetra-tert-butyl-5,10,15,20-tetraaza-21H,23H-porphine Exhibiting Bifunctional Sensitivity for Monitoring Chloramphenicol and Co²⁺”
by Ionela Fringu, Diana Anghel, Ion Fratilescu, Camelia Epuran, Mihaela Birdeanu and Eugenia Fagadar-Cosma
Biomedicines 2024, 12(4), 770; https://doi.org/10.3390/biomedicines12040770
Available online: https://www.mdpi.com/2227-9059/12/4/770

7. “Sinus Floor Augmentation with Synthetic Hydroxyapatite (NanoBone®) in Combination with Platelet-Rich Fibrin: A Case Series”
by Luís Francisco, Manuel Francisco, Rosana Costa, Miguel Nunes Vasques, Marta Relvas, António Rajão, Luís Monteiro, Paulo Rompante, Fernando Guerra and Marco Infante da Câmara
Biomedicines 2024, 12(8), 1661; https://doi.org/10.3390/biomedicines12081661
Available online: https://www.mdpi.com/2227-9059/12/8/1661

8. “Toxicological Assessment of Biodegradable Poli-ε-Caprolactone Polymer Composite Materials Containing Hydroxyapatite, Bioglass, and Chitosan as Potential Biomaterials for Bone Regeneration Scaffolds”
by Aleksandra Skubis-Sikora, Andrzej Hudecki, Bartosz Sikora, Patrycja Wieczorek, Mateusz Hermyt, Marek Hreczka, Wirginia Likus, Jarosław Markowski, Krzysztof Siemianowicz, Aleksandra Kolano-Burian et al.
Biomedicines 2024, 12(9), 1949; https://doi.org/10.3390/biomedicines12091949
Available online: https://www.mdpi.com/2227-9059/12/9/1949

9. “A General Method to Screen Nanobodies for Cytochrome P450 Enzymes from a Yeast Surface Display Library”
by Yudong Sun, Cristian Martinez-Ramos, Eugene Chen, Yoichi Osawa and Haoming Zhang
Biomedicines 2024, 12(8), 1863; https://doi.org/10.3390/biomedicines12081863
Available online: https://www.mdpi.com/2227-9059/12/8/1863

10. “Multifractal Analysis and Experimental Evaluation of MCM-48 Mesoporous Silica as a Drug Delivery System for Metformin Hydrochloride”
by Mousa Sha’at, Maria Ignat, Liviu Sacarescu, Adrian Florin Spac, Alexandra Barsan (Bujor), Vlad Ghizdovat, Emanuel Nazaretian, Catalin Dumitras, Maricel Agop, Cristina Marcela Rusu et al.
Biomedicines 2024, 12(12), 2838; https://doi.org/10.3390/biomedicines12122838
Available online: https://www.mdpi.com/2227-9059/12/12/2838

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:

This Section is currently open for submissions. Papers may be submitted via the following link:

https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:

If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The “Drug Discovery, Development and Delivery” Section publishes original and innovative scientific papers, as well as comprehensive review papers. In this context, we are pleased to feature some recently published papers in Biomedicines (ISSN: 2227-9059) on drug discovery, drug design, basic and clinical pharmacology, formulation and delivery, and toxicology, which will provide valuable insights into this exciting field.

1. “Aptamer-Based Smart Targeting and Spatial Trigger–Response Drug-Delivery Systems for Anticancer Therapy”
by Dongsik Park, Su Jin Lee and Jee-Woong Park
Biomedicines 2024, 12(1), 187; https://doi.org/10.3390/biomedicines12010187
Available online: https://www.mdpi.com/2227-9059/12/1/187

2. “The Use of Nigella sativa in Cardiometabolic Diseases”
by Giuseppe Derosa, Angela D’Angelo, Pamela Maffioli, Laura Cucinella and Rossella Elena Nappi
Biomedicines 2024, 12(2), 405; https://doi.org/10.3390/biomedicines12020405
Available online: https://www.mdpi.com/2227-9059/12/2/405

3. “Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance”
by Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butuca, Anca Maria Arseniu, Adina Frum, Luca Liviu Rus, Adriana Aurelia Chis, Anca Maria Juncan, Felicia Gabriela Gligor, Cecilia Georgescu et al.
Biomedicines 2024, 12(5), 953; https://doi.org/10.3390/biomedicines12050953
Available online: https://www.mdpi.com/2227-9059/12/5/953

4. “Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine”
by Francesco Gervasi and Fanny Pojero
Biomedicines 2024, 12(3), 502; https://doi.org/10.3390/biomedicines12030502
Available online: https://www.mdpi.com/2227-9059/12/3/502

5. “Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes”
by Matteo Nardin, Monica Verdoia, Simone Nardin, Davide Cao, Mauro Chiarito, Elvin Kedhi, Gennaro Galasso, Gianluigi Condorelli and Giuseppe De Luca
Biomedicines 2024, 12(4), 768; https://doi.org/10.3390/biomedicines12040768
Available online: https://www.mdpi.com/2227-9059/12/4/768

6. “Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects”
by Żaneta Słyk, Natalia Stachowiak and Maciej Małecki
Biomedicines 2024, 12(7), 1523; https://doi.org/10.3390/biomedicines12071523
Available online: https://www.mdpi.com/2227-9059/12/7/1523

7. “Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines”
by Nanami Irie, Kana Mizoguchi, Tomoko Warita, Mirai Nakano, Kasuga Sasaki, Jiro Tashiro, Tomohiro Osaki, Takuro Ishikawa, Zoltán N. Oltvai and Katsuhiko Warita
Biomedicines 2024, 12(3), 698; https://doi.org/10.3390/biomedicines12030698
Available online: https://www.mdpi.com/2227-9059/12/3/698

8. “Role of Functionalized Peptides in Nanomedicine for Effective Cancer Therapy”
by Kibeom Kim and Myoung-Hwan Park
Biomedicines 2024, 12(1), 202; https://doi.org/10.3390/biomedicines12010202
Available online: https://www.mdpi.com/2227-9059/12/1/202

9. “Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications”
by Tingting He, Daria Giacomini, Alessandra Tolomelli, Monica Baiula and Luca Gentilucci
Biomedicines 2024, 12(2), 316; https://doi.org/10.3390/biomedicines12020316
Available online: https://www.mdpi.com/2227-9059/12/2/316

10. “Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center”
by Jasmin Abu Arif, Vitus André Knecht, Anne Rübsam, Vanessa Lussac, Zohreh Jami, Dominika Pohlmann, Bert Müller and Uwe Pleyer
Biomedicines 2024, 12(5), 1106; https://doi.org/10.3390/biomedicines12051106
Available online: https://www.mdpi.com/2227-9059/12/5/1106

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

The “Cancer Biology and Oncology” Section publishes reviews and original peer-reviewed papers of a high scientific standard, covering all aspects of innovative cancer therapies. Papers aim to uncover novel therapeutic approaches toward overcoming conventional anticancer drug resistance and a better understanding of the interrelations between cancer and metabolism in addition to a better understanding of the tumor and its microenvironment, along with the discovery of novel diagnostic and prognostic makers. Topics include but are not limited to in vitro and in vivo cancer therapeutic responses, targeted therapies (including metabolism and immunotherapy, such as those involving CAR-T cells), identification of novel therapeutic targets, and evaluation of novel diagnosis and prognosis markers and the assessment of their impact on morphological, phenotypical, and molecular classifications.

1. “Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms”
by Theodoros Sidiropoulos, Nikolas Dovrolis, Hector Katifelis, Nikolaos V. Michalopoulos, Panagiotis Kokoropoulos, Nikolaos Arkadopoulos and Maria Gazouli
Biomedicines 2024, 12(5), 1040; https://doi.org/10.3390/biomedicines12051040
Available online: https://www.mdpi.com/2227-9059/12/5/1040

2. “IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia”
by Jonathan Paolino, Harrison K. Tsai, Marian H. Harris and Yana Pikman
Biomedicines 2024, 12(1), 89; https://doi.org/10.3390/biomedicines12010089
Available online: https://www.mdpi.com/2227-9059/12/1/89

3. “miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression”
by Francesca Maria Orlandella, Esther Imperlini, Katia Pane, Neila Luciano, Mariantonia Braile, Anna Elisa De Stefano, Paola Lucia Chiara Iervolino, Alessandro Ruocco, Stefania Orrù, Monica Franzese et al.
Biomedicines 2024, 12(3), 658. https://doi.org/10.3390/biomedicines12030658
Available online: https://www.mdpi.com/2227-9059/12/3/658

4. “Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer”
by Hänel W. Eberly, Bao Y. Sciscent, F. Jeffrey Lorenz, Eleni M. Rettig and Neerav Goyal
Biomedicines 2024, 12(2), 415; https://doi.org/10.3390/biomedicines12020415
Available online: https://www.mdpi.com/2227-9059/12/2/415

5. “Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes”
by Aleksandra Ciarka, Michał Piątek, Rafał Pęksa, Michał Kunc and Elżbieta Senkus
Biomedicines 2024, 12(4), 763; https://doi.org/10.3390/biomedicines12040763
Available online: https://www.mdpi.com/2227-9059/12/4/763

6. “Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging”
by Rita Saúde-Conde, Ayça Arçay Öztürk, Kosta Stosic, Oier Azurmendi Senar, Julie Navez, Christelle Bouchart, Tatjana Arsenijevic, Patrick Flamen and Jean-Luc Van Laethem
Biomedicines 2024, 12(3), 591; https://doi.org/10.3390/biomedicines12030591
Available online: https://www.mdpi.com/2227-9059/12/3/591

7. “Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification”
by Tomohiro Chiba
Biomedicines 2024, 12(4), 712; https://doi.org/10.3390/biomedicines12040712
Available online: https://www.mdpi.com/2227-9059/12/4/712

8. “Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer”
by Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, Giovanna Masci, Chiara Miggiano, Mariangela Gaudio, Chiara Benvenuti, Flavia Jacobs, Riccardo Gerosa, Armando Santoro et al.
Biomedicines 2024, 12(3), 500; https://doi.org/10.3390/biomedicines12030500
Available online: https://www.mdpi.com/2227-9059/12/3/500

9. “Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer”
by David K. Lau, Jack P. Collin and John M. Mariadason
Biomedicines 2024, 12(5), 1117; https://doi.org/10.3390/biomedicines12051117
Available online: https://www.mdpi.com/2227-9059/12/5/1117

10. “Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment”
by Agata M.Gawel, Anna Betkowska, Ewa Gajda, Marlena Godlewska and Damian Gawel
Biomedicines 2024, 12(8), 1822; https://doi.org/10.3390/biomedicines12081822
Available online: https://www.mdpi.com/2227-9059/12/8/1822

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:

This Section is currently open for submissions. Papers may be submitted via the following link:

https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:

If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office